On Tuesday, Supernus Pharmaceuticals SUPN will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
Supernus Pharmaceuticals EPS will likely be near 27 cents per share while revenue will be around $87.28 million, according to analysts.
In the same quarter last year, Supernus Pharmaceuticals reported EPS of 26 cents per share on revenue of $62.37 million. The Wall Street estimate would represent a 3.85 percent increase in the company's earnings. Revenue would be up 39.93 percent from the year-ago period.
Supernus Pharmaceuticals' reported EPS has stacked up against analyst estimates in the past like this:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | 0.27 | 0.24 | 0.24 | 0.26 |
EPS Actual | 0.29 | 0.32 | 0.19 | 0.26 |
Stock Performance
Over the last 52-week period, shares are up 55.42 percent. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Supernus Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.